Do not patronise medicines from bliss gvs pharma ltd, PARTNER OF TOBINCO PHARMACEUTICAL S LTD
Following the blacklisting of Bliss GVS Pharma Ltd, partner of Tobinco Pharmaceuticals Ltd, the FDA wishes to caution the general public that any hospital, pharmacy, licensed chemical shop or distributor of pharmaceutical product who has in stock any medicines from Bliss GVS Pharma should return them to the supplier with immediate effect.
This decision has been necessitated by the distribution of unregistered medicinal products and fake medicines onto the Ghanaian market by Bliss GVS Pharma Ltd. Dossiers/documentation submitted to the FDA from Bliss GVS Pharma Ltd, partner of Tobinco Pharmaceuticals have been found to be forged. This technically, makes the medicines fake. The FDA will therefore not proceed to analyse such medicinal products.
To date, Bliss GVS Pharma has failed to submit all the necessary documentation required for re-registration of the few medicinal products that were applied for re-registration. The manufacturer has about one hundred un-registered medicinal products.
The director of Bliss GVS Pharma admitted before officials of FDA that GSUNATE SUPPOSITORIES is a fake anti-malarial and it not used in India to treat malaria in children. Since they submitted forged dossier/documentation and also put fake medicines on the Ghanaian market, the FDA is cautioning the general public against patronising medicinal products manufactured by Bliss GVS Pharma Ltd, India.
All hospitals, pharmacies, distributors and licensed chemical shops who have in stock medicines from Bliss GVS Pharma should return them to the suppliers. Anybody found to deal in Bliss GVS products will be sanctioned. The World Health Organization has been accordingly informed of the ban placed on Bliss GVS Pharma Ltd.
Additionally, information from the general public on persons in any practice possible of endangering public health and safety with respect to FDA’s mandate is most welcome through any of the following contact numbers; 0244337235, 0544863418, 0244872556, 0244652336 or 0267265087.
DR STEPHEN K. OPUNI
CHIEF EXECUTIVE
